Supriya Lifescience Ltd
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]
- Market Cap ₹ 2,854 Cr.
- Current Price ₹ 355
- High / Low ₹ 602 / 292
- Stock P/E 16.9
- Book Value ₹ 76.5
- Dividend Yield 0.00 %
- ROCE 43.1 %
- ROE 34.3 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 93.1% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 45.2%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
|---|---|---|---|---|---|---|---|
| 184 | 213 | 278 | 312 | 385 | 530 | 552 | |
| 166 | 191 | 213 | 213 | 218 | 316 | 325 | |
| Operating Profit | 17 | 22 | 65 | 98 | 167 | 214 | 228 |
| OPM % | 9% | 10% | 23% | 32% | 43% | 40% | 41% |
| 7 | 9 | 8 | 11 | 11 | 8 | 10 | |
| Interest | 12 | 11 | 10 | 7 | 4 | 4 | 4 |
| Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 11 |
| Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 223 |
| Tax % | 30% | 40% | 31% | 24% | 26% | 27% | |
| Net Profit | 6 | 9 | 39 | 73 | 124 | 152 | 169 |
| EPS in Rs | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 21.77 |
| Dividend Payout % | 0% | 0% | 0% | 20% | 3% | 3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 24% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 93% |
| 3 Years: | 57% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 44% |
| 3 Years: | 45% |
| Last Year: | 34% |
Balance Sheet
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|
| 15 | 15 | 15 | 15 | 15 | 16 | |
| Reserves | 31 | 40 | 79 | 134 | 254 | 600 |
| 140 | 130 | 90 | 82 | 70 | 27 | |
| 55 | 60 | 69 | 105 | 107 | 92 | |
| Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 |
| 89 | 91 | 85 | 99 | 100 | 190 | |
| CWIP | 36 | 34 | 35 | 40 | 79 | 43 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| 117 | 120 | 133 | 197 | 267 | 502 | |
| Total Assets | 241 | 245 | 253 | 336 | 445 | 735 |
Cash Flows
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|
| 27 | 28 | 49 | 117 | 79 | 49 | |
| -27 | -5 | 5 | -25 | -47 | -60 | |
| -2 | -20 | -50 | -29 | -15 | 150 | |
| Net Cash Flow | -2 | 3 | 4 | 62 | 18 | 139 |
Ratios
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|
| Debtor Days | 99 | 92 | 79 | 60 | 70 | 79 |
| Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 |
| Days Payable | 121 | 112 | 110 | 130 | 145 | 91 |
| Cash Conversion Cycle | 91 | 64 | 45 | 61 | 131 | 160 |
| Working Capital Days | 119 | 97 | 96 | 49 | 90 | 132 |
| ROCE % | 14% | 37% | 50% | 60% | 43% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - With reference to the above captioned subject, please find enclosed newspaper advertisement published in Financial Express and Loksatta on Saturday, August 13, 2022, containing extract …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - Investor Presentation. You are requested to kindly take the same on record.
- Statement Of Deviation Or Variation In The Use Of Proceeds Of The Fresh Issue Of The Initial Public Offer Of The Company 12 Aug
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
12 Aug - Read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by ICICI …
- Unaudited Financial Results For The Quarter Ended June 30, 2022 12 Aug
Annual reports
No data available.
Concalls
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Jan 2022Transcript PPT
Niche Offerings[1]
The Company's focus is primarily on diverse therapeutic areas and niche products offerings of 38 APIs focused on diverse therapeutic segments. They have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between Fiscal 2017 and 2021. They were among the largest exporters of Salbutamol Sulphate contributing to 31% of the API exports from India in FY 2021 in volume terms.